Heron Therapeutics, Inc. (HRTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Heron Therapeutics, Inc. on August 13, 2026. The report details a corporate governance action regarding the company's Tax Benefit Preservation Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment and does not contain financial performance data.
Material Changes
On August 13, 2026, the Company entered into Amendment No. 1 to its Tax Benefit Preservation Plan, originally dated August 14, 2025. The primary material change is the extension of the "Final Expiration Date" of the Plan from August 14, 2026, to August 14, 2029.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the modification of security holder rights associated with the Tax Benefit Preservation Plan. The amendment was executed with Computershare Trust Company, N.A., acting as the rights agent.
Investor Verification Checklist
- Verify the full text of Amendment No. 1 to the Tax Benefit Preservation Plan (Exhibit 4.1) to understand any additional terms beyond the expiration date extension.
- Confirm the impact of the extended expiration date on the company's ability to preserve net operating losses or other tax attributes.
- Review the original Tax Benefit Preservation Plan dated August 14, 2025, to understand the baseline rights being modified.